Navigation Links
Patients and Physicians Express Desire to Switch to Transdermal Drug Delivery, Finds Frost & Sullivan

MOUNTAIN VIEW, Calif., July 11, 2013 /PRNewswire/ -- The $82 billion U.S. drug delivery market is showing no signs of saturation, with major patent expiries, generic competition, tightening Food and Drug Administration (FDA) regulations, and emerging drug delivery systems continuing to provide momentum. Among the 15 drug delivery systems surveyed by Frost & Sullivan, physicians prefer topical delivery, either as a transdermal patch or topical gel/cream, and expressed willingness to switch their current mode of therapy to one available in these forms.

A new end-user survey of more than 220 physicians and 650 patients by Frost & Sullivan, the Drug Delivery Technology: End-User Preferences, Utilization and Perceptions analysis (, finds that regardless of disease area, physicians select drug delivery methods that drive consistent patient compliance and effective outcomes. The survey traces usage patterns, analyzes preferences and opportunities among physicians and patients, and assesses their willingness to switch therapies based on the drug delivery method. DRUG DELIVERY METHODS AND DISEASE TYPES COVEREDDelivery MethodDisease TypeOral drug delivery

Type 1 diabetesNasal drug delivery

Type 2 diabetesTransdermal drug delivery

ObesityTopical drug delivery

Deep vein thrombosisSubcutaneous injection (autoinjector)

Arterial thrombosisSubcutaneous injection (prefilled syringe)

Atrial fibrillation/arrhythmiaIntramuscular injection (autoinjector)

Ischemic heart diseaseIntramuscular injection (prefilled syringe)

MigrainesIntradermal injection

Multiple SclerosisIntravenous injection

ADHDIntravenous infusion

SchizophreniaImplantable infusion pump

Alzheimer's diseaseExternal infusion pump


Ulcerative colitisRectal drug delivery

Crohn's diseasePsoriasisRheumatoid arthritisFor more information on this research, please email Britni Myers, Corporate Communications, at, with your full name, company name, job title, telephone number, company email address, company website, city, state and country.

The route of administration and drug delivery technology has a huge bearing on the adoption of, and compliance with, new as well as existing drugs. Among the surveyed physicians, only a quarter were considered early adopters of new drug delivery forms. Accordingly, manufacturers must listen to actual selection criteria and level of satisfaction data collected from end-users to find commercial success among medical practitioners.

"All things considered, physicians usually lean toward the treatment they feel will be most acceptable to their patients in order to ensure good compliance," said Frost & Sullivan Vice President of Global Research Monali Patel Shastry.

These indicators are highly relevant in the current market scenario, wherein medication adherence is a growing concern, with momentous medical and economic consequences.

"When selecting the optimal drug delivery method, reimbursement incentives for improving adherence and impact on formulary decisions are proven to be important factors," noted Frost & Sullivan Life Sciences Senior Industry Analyst Deborah Toscano. "Drug development pipelines are full of innovative drugs and biologics, and differentiation is increasingly important in this crowded market to gain and maintain market share."

It is important to note the drivers of satisfaction and selection are not always the same across diseases and methods. For example, the several novel oral therapies for multiple sclerosis recently introduced offer significant advantages over the standard of care injectable therapies. However, more than 55 percent of physicians treating multiple sclerosis are likely to switch from the currently prescribed branded drug if the drug were available in a transdermal patch form, while 54 percent of the physicians treating migraines would prefer to switch to a drug using nasal administration.

This is in line with the 58 percent of multiple sclerosis patients willing to use a transdermal patch, and 50 percent of migraine patients willing to use a nasally administered drug. Further, 57 percent of physicians treating type 2 diabetes are most willing to switch from oral or injectable drugs to a topical treatment.

The Drug Delivery Technology: End-User Preferences, Utilization and Perceptions analysis is generated by Frost & Sullivan's global Life Sciences practice.  Related research includes: Analysis of the Global Type 2 Diabetes Therapeutics Market, United States Market for Rheumatoid Arthritis Pharmacotherapeutics, and Strategic Analysis of Anti-Obesity Prescription Drug Development. All research services included in subscriptions provide detailed market opportunities and industry trends evaluated following extensive interviews with market participants.

Connect with Frost & Sullivan on social media, including Twitter, Facebook, SlideShare and LinkedIn, for the latest news and updates.

About Frost & SullivanFrost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants.

Our "Growth Partnership" supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.

  • The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.
  • The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.
  • For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?

    Contact Us:
    Start the discussion

    Join Us:
    Join our community

    Newsletter on "the next big thing"

    Gain access to visionary innovation

    Drug Delivery Technology: End-User Preferences, Utilization and PerceptionsContact:
    Britni Myers
    Corporate Communications – North America
    P: 210.477.8481
    F: 210.348.1003
    Twitter: @Frost_Sullivan
    Facebook: Frost & Sullivan

    SOURCE Frost & Sullivan
    Copyright©2012 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Senior Home Care Expands In-Home Telemonitoring to Serve Patients in The Villages, Fla. Area
    2. Respiratory Motion, Inc. Reports Important New Data On The ExSpiron Respiratory Monitor, The First Monitor To Provide Continuous Minute Ventilation Data In Non-Ventilated Patients
    4. Shaw Regional Cancer Center Chooses RAD Technologys Temporary Radiotherapy Vault System To Provide Continuous Care To Patients During New Linear Accelerator Installation
    5. Isis Reports Phase 2 Data on ISIS-APOCIII Rx Showing Significant Reductions in Triglycerides and APOC-III in Patients with High Triglycerides and Type 2 Diabetes
    6. Ibrutinib Monotherapy Clinical Trial Data in Patients with Waldenstroms Macroglobulinemia Presented at the International Conference on Malignant Lymphoma in Lugano, Switzerland
    7. New Risk Assessment Tool to Predict Stroke in Patients with Atrial Fibrillation
    8. Surveyed U.S. and European Neurologists Identify Better Seizure-Free Efficacy as One of the Greatest Unmet Needs in Treating Partial-Onset Seizures in Refractory Epilepsy Patients
    9. Traitement du cancer primaire du foie : létude SARAH désormais accessible aux patients concernés sur lensemble du territoire français
    10. Ibrutinib Phase 2 Study Results in Patients with Mantle Cell Lymphoma Published in The New England Journal of Medicine
    11. Ibrutinib Study Results in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Published in The New England Journal of Medicine
    Post Your Comments:
    (Date:11/30/2015)... MOUNTLAKE TERRACE, Wash. and ST. ... Cross and Express Scripts (NASDAQ: ESRX ) today ... benefit agreement. The partnership, which began in 1999, will ... --> --> After evaluating pharmacy ... process, Premera concluded that Express Scripts continues to offer ...
    (Date:11/30/2015)... Nov. 30, 2015 NHS Supply Chain ... TrueBeam™ machines from Varian Medical Systems (NYSE: ... to replace older machines and institute modern radiotherapy ... public hospitals. The order, placed in September, also ... for Varian,s RapidArc® and Eclipse™ software systems.    ...
    (Date:11/30/2015)... N.J. , Nov. 30, 2015  Novartis will ... at the 57 th American Society of Hematology ... lymphomas and myelomas as well as supportive care, including ... addition to personalized cell therapies. The ASH Annual Meeting ... Florida . Novartis Oncology . "We ...
    Breaking Medicine Technology:
    (Date:11/30/2015)... ... November 30, 2015 , ... The ... this summer, ushering in a new era of publicly accessible automated technology. Now, ... will continue to offer guests an up-close look at the shuttle at MOSI’s ...
    (Date:11/30/2015)... ... 2015 , ... On Saturday, October 24th, 2015, at the Mill Race Park ... a 5K walk known as “Making Strides Against Breast Cancer”. Patients and staff members ... located in Battle Creek, joined in for this campaign that sought to raise donations ...
    (Date:11/30/2015)... ... 30, 2015 , ... During the week of Thanksgiving, the ... for its research, education, support, and advocacy efforts. The campaign is held every ... Mesothelioma Applied Research Foundation, which also goes by Meso Foundation, holds the ...
    (Date:11/30/2015)... ... November 30, 2015 , ... According to Los Angeles bariatric surgeon Michael ... not necessarily caused by real hunger, but instead by a hormone called ghrelin ... that, while many patients are aware that weight loss surgery can help patients lose ...
    (Date:11/30/2015)... ... 30, 2015 , ... A record crowd gathered at the Pennsylvania Biotech Center ... Baruch S. Blumberg Institute. , The institute, which is the research arm of the ... leaders for the conference, which focused on ways companies can work to reduce the ...
    Breaking Medicine News(10 mins):